MA52483A - Dérivés de gip et leurs utilisations - Google Patents
Dérivés de gip et leurs utilisationsInfo
- Publication number
- MA52483A MA52483A MA052483A MA52483A MA52483A MA 52483 A MA52483 A MA 52483A MA 052483 A MA052483 A MA 052483A MA 52483 A MA52483 A MA 52483A MA 52483 A MA52483 A MA 52483A
- Authority
- MA
- Morocco
- Prior art keywords
- gip derivatives
- gip
- derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2235—Secretins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/645—Secretins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862666916P | 2018-05-04 | 2018-05-04 | |
| EP18172827 | 2018-05-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA52483A true MA52483A (fr) | 2021-03-10 |
Family
ID=66440040
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA052483A MA52483A (fr) | 2018-05-04 | 2019-05-03 | Dérivés de gip et leurs utilisations |
Country Status (20)
| Country | Link |
|---|---|
| US (3) | US10604555B2 (fr) |
| EP (1) | EP3788063B1 (fr) |
| JP (2) | JP6818940B2 (fr) |
| KR (1) | KR102379958B1 (fr) |
| CN (1) | CN112074531B (fr) |
| AU (1) | AU2019263674B2 (fr) |
| BR (1) | BR112020022027A2 (fr) |
| CA (1) | CA3097939A1 (fr) |
| CL (1) | CL2020002796A1 (fr) |
| CO (1) | CO2020014180A2 (fr) |
| ES (1) | ES2961384T3 (fr) |
| IL (1) | IL278171A (fr) |
| MA (1) | MA52483A (fr) |
| MX (1) | MX2020011427A (fr) |
| PE (1) | PE20210473A1 (fr) |
| PH (1) | PH12020551742A1 (fr) |
| RU (1) | RU2020136305A (fr) |
| SG (1) | SG11202010297UA (fr) |
| TW (1) | TWI707865B (fr) |
| WO (1) | WO2019211451A1 (fr) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR109595A1 (es) | 2016-09-09 | 2018-12-26 | Incyte Corp | Compuestos de pirazolopirimidina y usos de estos como inhibidores de hpk1 |
| US20180072718A1 (en) | 2016-09-09 | 2018-03-15 | Incyte Corporation | Pyrazolopyridine compounds and uses thereof |
| IL292977A (en) | 2016-09-09 | 2022-07-01 | Incyte Corp | Pyrazolopyridine derivatives as modulators of hpk1 and their use in cancer therapy |
| JP7526673B2 (ja) | 2018-02-20 | 2024-08-01 | インサイト・コーポレイション | がんを治療するためのｈｐｋ１阻害剤としてのｎ－（フェニル）－２－（フェニル）ピリミジン－４－カルボキサミド誘導体及び関連化合物 |
| US10752635B2 (en) | 2018-02-20 | 2020-08-25 | Incyte Corporation | Indazole compounds and uses thereof |
| RU2020136305A (ru) * | 2018-05-04 | 2022-05-05 | Ново Нордиск А/С | Производные gip и пути их применения |
| US10899755B2 (en) | 2018-08-08 | 2021-01-26 | Incyte Corporation | Benzothiazole compounds and uses thereof |
| KR20220059480A (ko) | 2019-08-06 | 2022-05-10 | 인사이트 코포레이션 | 고체 형태의 hpk1 억제제 |
| KR102886962B1 (ko) * | 2020-02-05 | 2025-11-17 | 일라이 릴리 앤드 캄파니 | 직렬 수지 반응기의 펩티드 합성기 |
| CN115884982A (zh) | 2020-03-06 | 2023-03-31 | 赛诺菲 | 作为选择性gip受体激动剂的肽 |
| JP7736315B2 (ja) | 2020-03-31 | 2025-09-09 | アンタロス メディカル アクティエボラーグ | イメージング及び治療目的のキレート部分を含む選択的ｇｉｐ受容体アゴニスト |
| US11478533B2 (en) | 2020-04-27 | 2022-10-25 | Novo Nordisk A/S | Semaglutide for use in medicine |
| AU2021312323A1 (en) | 2020-07-22 | 2023-02-02 | Novo Nordisk A/S | Co-agonists at GLP-1 and GIP receptors suitable for oral delivery |
| KR20230106616A (ko) * | 2020-11-09 | 2023-07-13 | 엠바크 바이오테크 에이피에스 | 타키키닌 수용체 매개 장애의 치료에 있어서의 화합물 및 이의 용도 |
| JP7805659B2 (ja) | 2021-06-23 | 2026-01-26 | ペプトロン インコーポレイテッド | セマグルチド又はその薬学的に許容可能な塩を含む徐放性製剤組成物 |
| MX2024002845A (es) | 2021-09-06 | 2024-04-30 | Sanofi Sa | Nuevos peptidos como agonistas potentes y selectivos del receptor de gip. |
| WO2023118263A1 (fr) * | 2021-12-21 | 2023-06-29 | Embark Biotech Aps | Agonistes pour le traitement d'un trouble de l'alimentation |
| TW202330584A (zh) | 2022-01-20 | 2023-08-01 | 丹麥商諾佛 儂迪克股份有限公司 | 前藥及其用途 |
| WO2023151594A1 (fr) * | 2022-02-11 | 2023-08-17 | Hangzhou Sciwind Biosciences Co., Ltd. | Composition comprenant des agonistes du récepteur gip et des agonistes du récepteur glp-1 et son utilisation |
| CN120500330A (zh) | 2022-12-16 | 2025-08-15 | 佩特通公司 | 包含glp-1受体激动剂或其药学上可接受的盐的缓释型微球及其用途 |
| CN118255864A (zh) * | 2022-12-26 | 2024-06-28 | 杭州中美华东制药有限公司 | Gip受体激动剂及其用途 |
| GB202302686D0 (en) * | 2023-02-24 | 2023-04-12 | Imperial College Innovations Ltd | Novel compounds |
| EP4669662A1 (fr) * | 2023-02-24 | 2025-12-31 | IP2IPO Innovations Limited | Composés |
| WO2025092778A1 (fr) * | 2023-10-31 | 2025-05-08 | 深圳信立泰药业股份有限公司 | Composé glp-1, son procédé de préparation et son utilisation |
| CN120349392A (zh) * | 2023-11-06 | 2025-07-22 | 成都奥达生物科技有限公司 | 一种gip激动剂化合物 |
| WO2025176999A2 (fr) * | 2024-02-23 | 2025-08-28 | Ip2Ipo Innovations Limited | Nouveaux composés |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE60012721T4 (de) | 1999-03-29 | 2010-09-09 | Uutech Ltd., Coleraine | Analoge des magensaft inhibierenden peptides und ihre verwendung für die behandlung von diabetes |
| GB0404124D0 (en) | 2004-02-25 | 2004-03-31 | Univ Ulster | Antagonists of GIP |
| TWI372629B (en) | 2005-03-18 | 2012-09-21 | Novo Nordisk As | Acylated glp-1 compounds |
| TWI474835B (zh) | 2008-06-17 | 2015-03-01 | Univ Indiana Res & Tech Corp | 用於治療代謝病症及肥胖症之基於ｇｉｐ之混合激動劑 |
| EA020018B1 (ru) | 2008-08-07 | 2014-08-29 | Ипсен Фарма С.А.С. | Процессированные аналоги глюкозозависимого инсулинотропного полипептида |
| MX2011001031A (es) | 2008-08-07 | 2011-04-26 | Ipsen Pharma Sas | Analogos de polipeptidos insulinotropicos dependientes de glucosa. |
| KR20110043688A (ko) | 2008-08-07 | 2011-04-27 | 입센 파마 에스.에이.에스 | 포도당 의존적인 인슐린 분비 자극성 폴리펩타이드 유사체 |
| CA2733006A1 (fr) * | 2008-08-07 | 2010-02-11 | Ipsen Pharma S.A.S. | Analogues de polypeptide insulinotrope glucose-dependant (gip) modifies a l'extremite n-terminale |
| CA2784757A1 (fr) * | 2009-12-16 | 2011-07-07 | Novo Nordisk A/S | Derives a double acylation de glp-1 |
| EP2528618A4 (fr) | 2010-01-27 | 2015-05-27 | Univ Indiana Res & Tech Corp | Conjugués d'antagoniste du glucagon et d'agoniste du gip et compositions pour le traitement de troubles métaboliques et de l'obésité |
| CA2797095A1 (fr) | 2010-05-13 | 2011-11-17 | Indiana University Research And Technology Corporation | Peptides de la superfamille des glucagons presentant une activite de recepteur nucleaire d'hormone |
| WO2011143208A1 (fr) | 2010-05-13 | 2011-11-17 | Indiana University Research And Technology Corporation | Peptides de la superfamille du glucagon manifestant une activité de récepteur couplé à une protéine g |
| US9249181B2 (en) * | 2010-09-13 | 2016-02-02 | Amylin Pharmaceuticals, Llc | C-terminal amidation of polypeptides |
| US9023986B2 (en) | 2010-10-25 | 2015-05-05 | Hoffmann-La Roche Inc. | Glucose-dependent insulinotropic peptide analogs |
| CA2822617A1 (fr) | 2010-12-22 | 2012-06-28 | Marcadia Biotech, Inc. | Methodes de traitement des affections metaboliques et de l'obesite faisant appel a des peptides associes au glucagon, actifs sur les recepteurs gip et glp-1 |
| US9453062B2 (en) * | 2011-06-10 | 2016-09-27 | Beijing Hanmi Pharmaceutical Co., Ltd. | Glucose dependent insulinotropic polypeptide analogs, pharmaceutical compositions and use thereof |
| WO2013003449A2 (fr) | 2011-06-27 | 2013-01-03 | Phasebio Pharmaceuticals, Inc. | Méthodes de traitement par des agonistes de récepteur du glp-1 |
| NZ702333A (en) * | 2012-05-03 | 2017-06-30 | Zealand Pharma As | Gip-glp-1 dual agonist compounds and methods |
| US9340600B2 (en) * | 2012-06-21 | 2016-05-17 | Indiana University Research And Technology Corporation | Glucagon analogs exhibiting GIP receptor activity |
| CN104583233B (zh) * | 2012-06-21 | 2018-10-23 | 印第安纳大学研究及科技有限公司 | 表现出gip受体活性的胰高血糖素的类似物 |
| JP6538645B2 (ja) | 2013-03-14 | 2019-07-03 | インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ | インスリン‐インクレチン複合物 |
| MY174727A (en) | 2013-04-18 | 2020-05-11 | Novo Nordisk As | Stable, protracted glp-1/glucagon receptor co-agonists for medical use |
| AR096440A1 (es) * | 2013-05-28 | 2015-12-30 | Takeda Pharmaceuticals Co | Compuesto peptídico agonista del receptor del péptido similar al glucagón tipo i (glp-1) y del péptido insulinotrópico dependiente de glucosa (gip) |
| EP3033112B1 (fr) | 2013-08-15 | 2020-10-07 | Novo Nordisk A/S | Dérivés glp-1 et leurs utilisations |
| WO2015022420A1 (fr) | 2013-08-16 | 2015-02-19 | Medimmune Limited | Agonistes doubles de récepteur de gip et glp-1 pour le traitement du diabète |
| AU2014345569B2 (en) | 2013-11-06 | 2020-08-13 | Zealand Pharma A/S | GIP-GLP-1 dual agonist compounds and methods |
| KR102310392B1 (ko) | 2013-11-06 | 2021-10-13 | 질랜드 파마 에이/에스 | 글루카곤-ｇｌｐ-1-ｇｉｐ 삼원 효능제 화합물 |
| US10570184B2 (en) * | 2014-06-04 | 2020-02-25 | Novo Nordisk A/S | GLP-1/glucagon receptor co-agonists for medical use |
| EP3189072B1 (fr) | 2014-09-05 | 2018-07-18 | University of Copenhagen | Peptides analogues du gip |
| RU2716985C2 (ru) | 2014-10-29 | 2020-03-17 | Зилэнд Фарма А/С | Соединения-агонисты gip и способы |
| EP3226906B1 (fr) * | 2014-11-27 | 2019-06-12 | Novo Nordisk A/S | Dérivés glp-1 et leurs utilisations |
| JO3575B1 (ar) * | 2015-01-09 | 2020-07-05 | Lilly Co Eli | مركبات مساعد مشترك من gip وglp-1 |
| WO2016138335A1 (fr) | 2015-02-27 | 2016-09-01 | Lycera Corporation | Thiadiazolamines indazolyle et composés apparentés pour l'inhibition de protéine kinase associée à rho et le traitement de maladies |
| WO2016205488A1 (fr) | 2015-06-17 | 2016-12-22 | The California Institute For Biomedical Research | Agents thérapeutiques modifiés et compositions associées |
| US20190175744A1 (en) | 2016-03-18 | 2019-06-13 | Merck Sharp & Dohme Corp. | Insulin-incretin conjugates |
| WO2017210168A1 (fr) | 2016-06-02 | 2017-12-07 | Indiana University Research And Technology Corporation | Agonistes hydrosolubles et chimiquement stables du depsi-glucagon |
| WO2018220123A1 (fr) * | 2017-05-31 | 2018-12-06 | University Of Copenhagen | Analogues peptidiques de gip à action prolongée |
| RU2020136305A (ru) * | 2018-05-04 | 2022-05-05 | Ново Нордиск А/С | Производные gip и пути их применения |
-
2019
- 2019-05-03 RU RU2020136305A patent/RU2020136305A/ru unknown
- 2019-05-03 SG SG11202010297UA patent/SG11202010297UA/en unknown
- 2019-05-03 JP JP2020512588A patent/JP6818940B2/ja active Active
- 2019-05-03 US US16/403,241 patent/US10604555B2/en active Active
- 2019-05-03 KR KR1020207034171A patent/KR102379958B1/ko not_active Expired - Fee Related
- 2019-05-03 TW TW108115352A patent/TWI707865B/zh not_active IP Right Cessation
- 2019-05-03 MA MA052483A patent/MA52483A/fr unknown
- 2019-05-03 ES ES19722582T patent/ES2961384T3/es active Active
- 2019-05-03 EP EP19722582.4A patent/EP3788063B1/fr active Active
- 2019-05-03 PE PE2020001751A patent/PE20210473A1/es unknown
- 2019-05-03 AU AU2019263674A patent/AU2019263674B2/en not_active Ceased
- 2019-05-03 CN CN201980029824.2A patent/CN112074531B/zh active Active
- 2019-05-03 BR BR112020022027-2A patent/BR112020022027A2/pt not_active Application Discontinuation
- 2019-05-03 WO PCT/EP2019/061413 patent/WO2019211451A1/fr not_active Ceased
- 2019-05-03 MX MX2020011427A patent/MX2020011427A/es unknown
- 2019-05-03 CA CA3097939A patent/CA3097939A1/fr not_active Withdrawn
- 2019-05-03 US US17/052,702 patent/US11633459B2/en active Active
-
2020
- 2020-04-09 JP JP2020070421A patent/JP2020125311A/ja not_active Withdrawn
- 2020-10-20 PH PH12020551742A patent/PH12020551742A1/en unknown
- 2020-10-20 IL IL278171A patent/IL278171A/en unknown
- 2020-10-28 CL CL2020002796A patent/CL2020002796A1/es unknown
- 2020-11-12 CO CONC2020/0014180A patent/CO2020014180A2/es unknown
-
2023
- 2023-02-03 US US18/105,419 patent/US20240190938A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CA3097939A1 (fr) | 2019-11-07 |
| EP3788063C0 (fr) | 2023-08-09 |
| JP2020528925A (ja) | 2020-10-01 |
| US20220000982A1 (en) | 2022-01-06 |
| CL2020002796A1 (es) | 2021-02-19 |
| PH12020551742A1 (en) | 2021-06-28 |
| CN112074531B (zh) | 2025-04-15 |
| AU2019263674B2 (en) | 2023-03-02 |
| BR112020022027A2 (pt) | 2021-02-02 |
| US11633459B2 (en) | 2023-04-25 |
| KR102379958B1 (ko) | 2022-04-01 |
| JP6818940B2 (ja) | 2021-01-27 |
| RU2020136305A (ru) | 2022-05-05 |
| ES2961384T3 (es) | 2024-03-11 |
| US20190367578A1 (en) | 2019-12-05 |
| AU2019263674A1 (en) | 2020-11-26 |
| IL278171A (en) | 2020-11-30 |
| SG11202010297UA (en) | 2020-11-27 |
| PE20210473A1 (es) | 2021-03-08 |
| TWI707865B (zh) | 2020-10-21 |
| US10604555B2 (en) | 2020-03-31 |
| JP2020125311A (ja) | 2020-08-20 |
| KR20210005700A (ko) | 2021-01-14 |
| US20240190938A1 (en) | 2024-06-13 |
| MX2020011427A (es) | 2020-12-07 |
| EP3788063B1 (fr) | 2023-08-09 |
| WO2019211451A1 (fr) | 2019-11-07 |
| CO2020014180A2 (es) | 2021-01-29 |
| EP3788063A1 (fr) | 2021-03-10 |
| TW202003550A (zh) | 2020-01-16 |
| CN112074531A (zh) | 2020-12-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3706762A4 (fr) | N4-hydroxycytidine et dérivés et leurs utilisations anti-virales | |
| EP3788055A4 (fr) | Dérivés de neurostéroïdes et leurs utilisations | |
| EP3917529A4 (fr) | Composés et leurs utilisations | |
| EP3841096A4 (fr) | Dérivés de pyridinylméthylènepipéridine et leurs utilisations | |
| MA50256A (fr) | Composés de pyrazolopyrimidinone et leurs utilisations | |
| EP3694861A4 (fr) | Composés hétérocycliques et leurs utilisations | |
| EP3787607C0 (fr) | Compositions de caroténoïdes et leurs utilisations | |
| EP3849983A4 (fr) | Composés de triazolo-pyrimidine et leurs utilisations | |
| MA50618A (fr) | Polyrhérapies et leurs utilisations | |
| EP3917527A4 (fr) | Composés et leurs utilisations | |
| MA52365A (fr) | Composés et leurs utilisations | |
| MA52092A (fr) | Composés et leurs utilisations | |
| EP3313530A4 (fr) | Dérivés de 4,6-pyrimidinylène et utilisations de ceux-ci | |
| MA55385A (fr) | Composés et leurs utilisations | |
| EP3902530A4 (fr) | Nanovaccins polymères et leurs utilisations | |
| MA50413A (fr) | Dérivés de benzimidazole et leurs utilisations | |
| EP3790883A4 (fr) | Composés hétéroaryles et leurs utilisations | |
| EP3853216A4 (fr) | Composés substitués par pyridinyle et leurs utilisations | |
| EP4017843A4 (fr) | Dérivés de benzènesulfonamide et leurs utilisations | |
| EP3526215A4 (fr) | Dérivés de n-acyléthanolamide et leurs utilisations | |
| EP3323817A4 (fr) | Dérivés d'aniline pyrimidine et leurs utilisations | |
| MA52411A (fr) | Dérivés de 2,4-diaminoquinazoline et leurs utilisations médicales | |
| MA52976A (fr) | Dérivés de tétrahydrothiénopyridine n-substitués et leurs utilisations | |
| EP3535243A4 (fr) | Dérivés hétérocycliques tricycliques et leurs utilisations | |
| EP3630154A4 (fr) | Dérivés clivables de lipo-glycopeptides et leurs utilisations |